Neuren Pharmaceuticals Ltd NURPF
$15.51
Last Updated: Aug 18, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
NURPF Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Neuren Pharmaceuticals Ltd is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Neuren Pharmaceuticals Ltd. Stock Analysis NURPF
United States Health Care Mid Cap Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
Neuren Pharmaceuticals Ltd (NURPF) Chart
Financial Metrics & Statements of Neuren Pharmaceuticals Ltd (NURPF)
FAQ's for Neuren Pharmaceuticals Ltd (NURPF)
- As of August 2026, Neuren Pharmaceuticals Ltd NURPF is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neuren Pharmaceuticals Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Neuren Pharmaceuticals Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Neuren Pharmaceuticals Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Neuren Pharmaceuticals Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Neuren Pharmaceuticals Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Neuren Pharmaceuticals Ltd (NURPF)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
